Literature DB >> 15823553

5-amino-imidazole carboxamide riboside acutely potentiates glucose-stimulated insulin secretion from mouse pancreatic islets by KATP channel-dependent and -independent pathways.

Chang-Zheng Wang1, Yong Wang, Anke Di, Mark A Magnuson, Honggang Ye, Michael W Roe, Deborah J Nelson, Graeme I Bell, Louis H Philipson.   

Abstract

AMP-activated protein kinase (AMPK) is an important signaling effector that couples cellular metabolism and function. The effects of AMPK activation on pancreatic beta-cell function remain unresolved. We used 5-amino-imidazole carboxamide riboside (AICAR), an activator of AMPK, to define the signaling mechanisms linking the activation of AMPK with insulin secretion. Application of 300 microM AICAR to mouse islets incubated in 5-14 mM glucose significantly increased AMPK activity and potentiated insulin secretion. AICAR inhibited ATP-sensitive K(+) (K(ATP)) channels and increased the frequency of glucose-induced calcium oscillations in islets incubated in 8-14 mM glucose. At lower glucose concentration (5mM) AICAR did not affect K(ATP) activity or intracellular ([Ca(2+)](i)). AICAR also did not inhibit (86)Rb(+) efflux from islets isolated from Sur1(-/-) mice that lack K(ATP) channels yet significantly potentiated glucose stimulated insulin secretion. Our data suggest that AICAR stimulates insulin secretion by both K(ATP) channel-dependent and -independent pathways.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15823553     DOI: 10.1016/j.bbrc.2005.03.093

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  19 in total

1.  AICAR inhibits oxygen consumption by intact skeletal muscle cells in culture.

Authors:  Espen E Spangenburg; Kathryn C Jackson; Rosemary A Schuh
Journal:  J Physiol Biochem       Date:  2013-06-30       Impact factor: 4.158

2.  Per-arnt-sim (PAS) domain kinase (PASK) as a regulator of glucagon secretion.

Authors:  P E MacDonald; P Rorsman
Journal:  Diabetologia       Date:  2011-02-17       Impact factor: 10.122

3.  AMP-activated protein kinase connects cellular energy metabolism to KATP channel function.

Authors:  Hidetada Yoshida; Li Bao; Eirini Kefaloyianni; Eylem Taskin; Uzoma Okorie; Miyoun Hong; Piyali Dhar-Chowdhury; Michiyo Kaneko; William A Coetzee
Journal:  J Mol Cell Cardiol       Date:  2011-08-24       Impact factor: 5.000

4.  Loss of AMP-activated protein kinase alpha2 subunit in mouse beta-cells impairs glucose-stimulated insulin secretion and inhibits their sensitivity to hypoglycaemia.

Authors:  Craig Beall; Kaisa Piipari; Hind Al-Qassab; Mark A Smith; Nadeene Parker; David Carling; Benoit Viollet; Dominic J Withers; Michael L J Ashford
Journal:  Biochem J       Date:  2010-07-15       Impact factor: 3.857

5.  AMP-activated protein kinase regulates hERG potassium channel.

Authors:  Ahmad Almilaji; Carlos Munoz; Bernat Elvira; Abul Fajol; Tatsiana Pakladok; Sabina Honisch; Ekaterina Shumilina; Florian Lang; Michael Föller
Journal:  Pflugers Arch       Date:  2013-05-29       Impact factor: 3.657

6.  Serine-385 phosphorylation of inwardly rectifying K+ channel subunit (Kir6.2) by AMP-dependent protein kinase plays a key role in rosiglitazone-induced closure of the K(ATP) channel and insulin secretion in rats.

Authors:  T-J Chang; W-P Chen; C Yang; P-H Lu; Y-C Liang; M-J Su; S-C Lee; L-M Chuang
Journal:  Diabetologia       Date:  2009-04-09       Impact factor: 10.122

Review 7.  Regulation of ion channels and transporters by AMP-activated kinase (AMPK).

Authors:  Florian Lang; Michael Föller
Journal:  Channels (Austin)       Date:  2013-12-23       Impact factor: 2.581

8.  Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients.

Authors:  H Boon; M Bosselaar; S F E Praet; E E Blaak; W H M Saris; A J M Wagenmakers; S L McGee; C J Tack; P Smits; M Hargreaves; L J C van Loon
Journal:  Diabetologia       Date:  2008-08-16       Impact factor: 10.122

9.  Pioglitazone acutely reduces insulin secretion and causes metabolic deceleration of the pancreatic beta-cell at submaximal glucose concentrations.

Authors:  Julien Lamontagne; Emilie Pepin; Marie-Line Peyot; Erik Joly; Neil B Ruderman; Vincent Poitout; S R Murthy Madiraju; Christopher J Nolan; Marc Prentki
Journal:  Endocrinology       Date:  2009-04-30       Impact factor: 4.736

10.  Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice.

Authors:  S Franckhauser; I Elias; V Rotter Sopasakis; T Ferré; I Nagaev; C X Andersson; J Agudo; J Ruberte; F Bosch; U Smith
Journal:  Diabetologia       Date:  2008-04-24       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.